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Purpose: Intensive care unit patients usually have a deregulated glucose homeostasis and present 
with hyperglycemia and hyperinsulinemia, suggesting overall insulin resistance. Adiponectin 
has significant anti-inflammatory and insulin-sensitizing effects and is diminished in morbidly 
obese and in critically ill patients. Reduced adiponectin could contribute to insulin resistance 
in these patients. We examined how far insulin demand in critically ill patients is correlated 
with patient adiponectin levels.
Patients and methods: Adiponectin, resistin, leptin, insulin demand, minimal and maximal 
blood sugar levels, epinephrine, and hydrocortisone demand were measured 1 day after diagnosis 
of severe sepsis or septic shock in 25 patients (8 female, 17 male; median age 65 years; range: 
31 to 87 years).
Results: Insulin demand (range: 0–8 IU/h; median 3.5 IU) was positively correlated 
with serum adiponectin levels (median: 10.1 µg/mL; range: 2.9–47.6 µg/mL; r = +0.56, 
P , 0.01). There was no significant correlation between insulin demand and leptin serum 
levels (median: 18.1 ng/mL; range: 0.3–80.7 ng/mL; r = +0.29, P = 0.08) or resistin serum levels 
(median: 103.9 ng/mL; range: 14.7–352.3 ng/mL; r = +0.13, P = 0.27). Epinephrine demand 
(median: 0.08 µg/kg*min; range: 0.02–0.63 µg/kg*min) was negatively correlated with male 
adiponectin levels (r = -0.58; P , 0.01; females: r = -0.36; P = 0.19) and positively correlated 
with resistin levels (r = 0.43; P = 0.02). Patient body mass index (median 26 kg/m²; range: 
18–37) was positively correlated with serum leptin (r = 0.60; P , 0.01) but was not correlated 
with insulin demand (r = 0.19; P = 0.19), or adiponectin (females: r = -0.37, P = 0.18; males: 
r = -0.16, P = 0.27), or resistin levels (r = +0.17; P = 0.21).
Conclusion: Adiponectin levels and insulin demand were positively correlated during sepsis. 
Adiponectin levels were negatively correlated with epinephrine demand in male patients and 
epinephrine demand was positively correlated with resistin levels, which might have increased 
insulin resistance. The relationship between adiponectin and insulin action in humans is more 
complex than often suggested.
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Introduction
Patients who are critically ill often require prolonged intensive care and vital organ 
function support. These patients uniformly have a deregulated glucose homeostasis 
and present with hyperglycemia and hyperinsulinemia, suggesting overall insulin 
resistance. Maintaining normoglycemia with insulin therapy improves survival and 
reduces morbidity in surgical intensive care unit patients.1,2
Hyperglycemia in the presence of hyperinsulinemia also accompanies type 2 diabetes 
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reduced inhibition of hepatic gluconeogenesis and impaired 
glucose uptake in   insulin-sensitive tissues, such as skeletal 
muscle.3
These metabolic processes are influenced by products of the 
adipose tissue, so-called adipokines, which play a crucial role in 
the pathogenesis of the metabolic syndrome. Adipokine levels 
are changed in the morbidly obese and these changed levels 
contribute to skeletal muscle and hepatic insulin resistance.4
Adiponectin, the most abundant adipokine exclusively 
derived from adipocytes with higher average levels in females 
compared with males, has excited intense interest because of 
robust correlation of its circulating levels with insulin resis-
tance and risk of T2DM. Further, adiponectin has a significant 
anti-inflammatory and insulin-sensitizing effect.5,6 We have 
already demonstrated that adipokines like adiponectin or leptin 
are shifted in critically ill patients in the same direction as in 
morbidly obese and patients with T2DM.7 Adiponectin has an 
unusual inverse relationship with body mass index (BMI) and 
thus is diminished in the obese, but also in the critically ill.7,8 
Since reduced adiponectin levels seems to contribute to insulin 
resistance in the obese, reduced adiponectin levels could also 
contribute to insulin resistance in critically ill patients.
Since higher adiponectin levels are associated with a 
lower risk of T2DM across diverse populations,9 we could 
speculate that higher adiponectin levels in critically ill 
patients cause a lower insulin demand.
Therefore, in this study, we determined adiponectin, resis-
tin, and leptin levels in critically ill patients and analyzed the 
insulin demand in correlation to patients’ adipokine levels.
Materials and methods
Patient characteristics
Twenty-five patients who fulfilled the clinical criteria for 
severe sepsis or septic shock were enrolled in this study. Eight 
patients were female and 17 male, with a median age of 65 
years (range: 31–87 years; female median age: 81 years, range: 
42–87 years; male median age: 65 years, range: 31–83 years). 
The criteria for severe sepsis and septic shock were in accor-
dance with those defined by Bone.10 The Simplified Acute 
Physiology Score (SAPS II) and Sequential Organ Failure 
Assessment score (SOFA) without Glasgow Coma Scale were 
used to define the severity of disease and organ dysfunctions, 
respectively.11–13 Total adiponectin, resistin, and leptin were 
measured 1 day after diagnosis of severe sepsis or septic shock. 
Blood samples were collected at 5 am in the fasting state. Body 
weight and height for calculation of BMI of septic patients 
were self-reported (or estimated if no self-report was possible). 
Insulin was administered via perfusor syringe. International 
Units of insulin demand, minimal and maximal blood sugar 
levels, as well as epinephrine and hydrocortisone demand were 
determined within the first 24 hours after diagnosis of severe 
sepsis or septic shock.
For all measurements, 10 mL venous blood was collected 
in a chilled syringe with EDTA and immediately centrifuged 
at 1600 × g for 15 minutes. Plasma was stored at -80°C until 
analysis.
The study was performed with the permission of the 
independent local ethics committee of the University of 
Ulm (approval number 82/2002 and 73/2009). A written 
informed consent was obtained. If the patient was not capable 
of making decisions because of sedation or altered mental 
function, the informed consent was obtained after recovery 
as advised by the ethics committee. Exclusion criteria were: 
age ,18 years, pregnancy, rapidly progressing underlying 
disease, HIV/AIDS, cardiogenic shock as the primary 
underlying disease, underlying hematologic disease, or 
cytotoxic therapy given within the previous 6 months.
Adipokine measurement and reagents
Multiplex analysis kits for leptin, resistin, and total adiponectin 
were obtained from Millipore, Hamburg,   Germany. In brief, 
the appropriate adipokine standards and samples, diluted in 
plasma dilution buffer, were added to wells of a filtered plate. 
The samples were incubated with 50 µL of the antibody-
coupled microsphere set on a plate shaker in the dark at room 
temperature for 30 minutes. The samples were washed 3 times 
with 100 µL wash puffer. Freshly diluted secondary detec-
tion antibody (25 µL/well) was added to the wells and then 
incubated on a plate shaker in the dark at room temperature. 
Thereafter, samples were washed 3 times with 100 µL wash 
buffer. Fifty microliters of strepavidin-PE (16 µg/mL in assay 
buffer) was added to each well, and incubation continued on 
a plate shaker at room temperature for the first 10 minutes. 
Unbound analytes were filtered through the wells using the 
vacuum manifold. The bound beads were washed 3 times 
with 100 µL wash buffer. After the last wash step, 125 µL of 
assay buffer was added to each well and the plate was placed 
on a plate shaker set at 500 rpm for 1 minute and then for 
3 minutes at a reduced speed of 300 rpm. Finally, samples 
were analyzed on the Luminex system in accordance with 
the manufacturers’ instructions. The system was sufficiently 
sensitive to analyze leptin values as low as 0.3 ng/mL.
Statistical analysis
All values were expressed as median with range. The Mann-
Whitney U test was used to compare the data of septic 
patients. Analysis was performed with WinSTAT, Version 
2009.1 (R.F. FitchSoftware).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The Spearman rank-order correlation coefficient was 
calculated for correlation analysis. R indicates the correlation 
coefficient. A value of P , 0.05 was considered statistically 
significant. Correlation coefficient values between 0.3 and 
0.7 (-0.3 and -0.7) indicate a moderate linear relationship, 
and values between 0.7 and 1.0 (-0.7 and -1.0) indicate a 
strong positive (negative) linear relationship. No adjustment 
for multiple testing has been made.
Results
The 25 septic patients (17 male and 8 female patients) had 
median SAPS II and SOFA scores of 37 (range: 21–58) and 
9 (3–11), respectively. Median BMI was 26 kg/m² (range: 
18–37). The underlying cause of sepsis with side diagnosis, 
gender, age, CRP and leukocyte levels, BMI, SAPS II (with-
out Glasgow Coma Scale), and sepsis score according to the 
definition of Bone et al10 are shown in Table 1.
Table 1 gender, age, underlying reason of sepsis, side diagnosis, c-reactive protein levels, white blood count, self-reported (or 
estimated) body mass index, and Simplified Acute Physiology Score (SAPS II) without Glasgow Coma Scale of the 25 septic patients
Age/ 
gender
Underlying  
cause of sepsis
CRP (mg/L) White  
bloodcount  
(G/l)
BMI Side  
diagnosis
SAPS II  
(without  
GCS)
SOFA  
(without  
GCS)
Sepsis   
scorea 
62/m Acute necrotizing  
pancreatitis
85 12.7 27 Spastic hemi paresis,  
nicotine and AA/D
49 10 6
83/m Perforated  
gastric ulcer
334 44.8 25 niDDM, aHT, TAA 50 10 6
67/m Postoperative  
pancreatic fistula
259 46.2 29 niDDM, aHT 21 7 6
42/f necrotizing fasciitis 323 17.5 28 – 58 9 7
65/m necrotizing fasciitis 283 24.3 25 DiDDM, aHT,  
TAA, ri
29 11 6
66/m ischemic colitis 289 18.2 26 DiDDM, aHT;  
ri; PAOD
34 9 6
63/m Postoperative  
bile peritonitis
266 12.9 37 cHD, adipositas,  
niDDM, aHT
31 9 6
64/m Postoperative  
paralytic ileus
250 16.2 30 – 24 10 6
86/f Perforated  
duodenal ulcers
273 37.7 31 aHT, dementia 31 5 4
50/m esophageal  
perforation
138 15.5 26 nicotine and AA/D;  
liver cirrhosis
40 11 6
69/m Acute necrotizing  
pancreatitis
219 14.7 23 nicotine and AA/D 24 8 6
44/m Blunt chest trauma 135 9.7 32 – 29 9 6
67/m colon anastomosis  
insufficiency
319 28,9 21 Ulcerative colitis 47 11 6
65/m Arterial bypass infection 259 17.5 26 PAOD, AA/D,  
cOPD, HF
37 9 6
58/f gastric ulcers  
peroration
259 16.9 32 nicotine and  
AA/D, liver cirrhosis,  
aHT, asthma
53 10 6
31/m Pleural empyema 330 17.5 28 – 29 7 6
64/m colon anastomosis  
insufficiency
102 21.6 23 – 46 11 6
66/m gastric ulcers peroration 200 26.7 24 cHD, PAOD, cOPD 48 9 4
87/f gastric ulcers peroration 213 16.3 22 aHT, TAA, HF 41 5 4
80/f Anaphylactic shock 134 14.3 25 niDDM, aHT 54 5 5
81/f Postoperative  
abdominal infection
274 37.3 24 cOPD 46 6 6
87/f Aspiration pneumonia 235 18.9 28 cOPD 54 9 6
50/f retroperitoneal abscess 178 18.8 26 ri, aHT 31 3 4
44/m necrotizing fasciitis 130 15.1 31 nicotine and AA/D, ri 28 6 6
80/m empyema 225 17.6 18 cOPD, nicotine  
abuse, ri
31 9 4
Note: aSepsis score (Bone et al10): 4, sepsis, 5, severe sepsis, 6, septic shock.
Abbreviations: AA/D, alcohol abuse/dependence; aHT, arterial hypertension; cHD, coronary heart disease; cOPD, chronic obstructive pulmonary disease; crP, c-reactive 
protein; gcS, glasgow coma Scale; g/i, giga/liter; HF, heart failure; niDDM, noninsulin dependent diabetes mellitus; PAOD, peripheral artery occlusive disease; ri, renal 
insufficiency; TAA, tachyarrhythmia absoluta.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Median resistin level was 103.9 ng/mL (range: 
14.7–352.3 ng/mL), median leptin level was 18.1 ng/mL 
(range: 0.3–80.7 ng/mL). Median gender specific adiponec-
tin serum levels were 14.1 µg/mL for female (range: 5.3–
47.6 µg/mL) and 9.6 µg/mL (range: 2.9–32.6 µg/mL) for male 
patients. The 2 extreme values of adiponectin (47.6 µg/mL in 
female patients and 32.6 µg/mL in male patients) represent 
the 2 patients with the lowest BMI (22 kg/m2 and 18 kg/m2) 
and the lowest leptin levels (0.9 ng/mL and 0.3 ng/mL, 
respectively), although BMI showed no significant nega-
tive correlation with adiponectin levels (females: r = -0.37, 
P = 0.18; males: r = -0.16, P = 0.27).
Minimal blood sugar levels ranged between 63 mg/dL and 
119 mg/dL (median 91 mg/dL), and maximal levels ranged 
from 122 to 398 mg/dL (median 193 mg/dL).
Insulin demand ranged from 0 to 8 IU/h (median 3.5 IU/h). 
When sepsis was diagnosed, 23 out of 25 patients required 
insulin; 15 out of 25 patients required hydrocortisone (pre-
ponderant 8 mg/h; range: 0–10 mg/h), and all septic patients 
required epinephrine (median: 0.08 µg/kg*min; range: 
0.02–0.63 µg/kg*min). There was no gender difference in 
resistin and leptin levels, insulin, hydrocortison, and adrenalin 
demand or in minimal and maximal blood sugar levels.
There was a positive correlation of insulin demand after 
diagnosis of sepsis and serum adiponectin levels (all patients: 
r = +0.57, P , 0.01; female patients: r = +0.61, P = 0.05; 
Figure 1A; male patients: r = +0.53, P = 0.01;   Figure 1B). 
Multivariate regression analyses with adjustment for age 
and BMI showed a largely unchanged significant positive 
  correlation between insulin demand after diagnosis of sepsis 
and serum adiponectin levels (P = 0.02; 95% confidence 
interval: 0.02–0.2). There was no significant correlation 
between insulin demand and leptin (r = +0.29, P = 0.08) or 
resistin (r = +0.13, P = 0.27; Table 2) serum levels.
Epinephrine demand was negatively correlated with 
male adiponectin levels (r = -0.58; P , 0.01; female: 
r = -0.36; P = 0.19) and positively correlated with resistin 
levels (r = 0.43; P = 0.02; Table 2). There was no correlation 
between epinephrine and insulin (r = 0.12; P = 0.28) and 
leptin (r = 0.24; P = 0.13).
Patients who received hydrocortisone (n = 15) had 
mean insulin demand of 5 IU/h (range: 1.0–8.0 IU/h), while 
patients who received no hydrocortisone (n = 10) had mean 
insulin demand of 2 IU/h (range: 0.0–5.0 IU/h; P = 0.01). 
The mean adiponectin levels were not significantly different 
regardless of whether patients received hydrocortisone 
(10.3 µg/mL vs 10.0 µg/mL; P = 0.20). Furthermore, 
groups showed no difference in SAPS II and SOFA scores 
(P = 0.46; P = 0.41).
There was no correlation between patient age and 
SAPS II and SOFA scores, insulin, hydrocortisone, and 
adrenalin demand, or any analyzed serum parameter 
  (adiponectin, resistin, and leptin). Five patients had 
  pre-existing T2DM. These 5 patients showed no difference 
in any analyzed parameter.
Patient BMI was positively correlated with serum leptin 
(r = 0.60; P , 0.01) but not with insulin demand (r = 0.19; 
P = 0.19), or adiponectin (female: r = -0.37, P = 0.18; male: 
r = -0.16, P = 0.27), or resistin (r = +0.17; P = 0.21) levels.
Discussion
Adipose tissue is essentially involved in complex body 
hormone and cytokine production and cannot stand 
by passively in septic conditions. In septic conditions, 
adipokines are shifted in the same direction as in obese 
subjects and patients with T2DM, which implies lowered 
serum levels of adiponectin. Recent research indicated that 
adiponectin has anti-inflammatory, anti-atherogenic, and 
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Figure 1 A,B) insulin demand after diagnosis of sepsis and serum adiponectin levels of female (Figure 1A) and male (Figure 1B) patients. The 2 extreme values of adiponectin 
(47.6 µg/mL in female patients and 32.6 µg/mL in male patients) represent the 2 patients with the lowest body mass index (22 kg/m2 and 18 kg/m2) and the lowest leptin 
levels (0.9 ng/mL and 0.3 ng/mL, respectively), although body mass index showed no significant negative correlation with adiponectin levels (females: r = -0.37, P = 0.18; 
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antidiabetic properties. The ability of adiponectin to reduce 
insulin resistance in conjunction with its anti-inflammatory 
properties makes adiponectin a potentially promising 
therapeutic target, and agents that enhance adiponectin 
secretion or action have potential to treat metabolic 
disease.14
Because lowered adiponectin levels are associated with 
insulin resistance,15 we hypothesized that patients with 
lower adiponectin serum levels in septic conditions have 
a higher insulin demand. Surprisingly, however, insulin 
demand showed a positive correlation to serum adiponectin 
levels – especially since direct testing of the effect of insulin 
infusion in healthy subjects has shown that insulin suppresses 
adiponectin levels in vivo.16
A possible rationale for this unexpected correlation may 
be that adiponectin levels are more influenced by the septic 
condition than adiponectin levels influence insulin demand, 
particularly since adiponectin levels correlate negatively with 
SAPS II and SOFA scores.7
Furthermore, insulin secretion is influenced by multiple 
hormones. Besides adipose tissue-derived hormones, a 
variety of other hormones has been discovered in recent 
years. Possible candidate hormones that can enhance insulin 
secretion are the so-called incretins, ie, gut peptide hormones, 
which are secreted in response to a meal.17 Referring to 
insulin demand, these hormones could be more involved 
compared with adiponectin through their insulin-secreting 
effect, although incretins seem to be responsible for higher 
insulin release after an oral glucose load compared with an 
intravenous glucose load.18
In addition to incretins, there are also a number of other 
hormones like ghrelin or peptide YY. Ghrelin has been shown 
to inhibit insulin secretion in humans19 and ghrelin levels 
seem to be elevated in fasting conditions.20 Similarly, recent 
studies have suggested more direct effects of peptide YY on 
insulin sensitivity,21 but the role of peptide YY independent 
of food intake still needs to be confirmed. Since all septic 
patients enrolled in this study were fed exclusively parenter-
ally, the insulin-secreting stimulus of incretins and other 
gut hormones was expected to be reduced.22 No data exist 
to show the extent to which septic conditions influence gut 
hormone release.
It is difficult to say how patient insulin demand in this 
study was influenced by hydrocortisone supply. Insulin 
resistance in critically ill patients and patients with systemic 
inflammatory response syndrome was classically attributed 
to increased serum levels of cortisol, which promotes 
gluconeogenesis and inhibits peripheral glucose disposal 
in a stress-dependent manner.23 Ten out of 25 patients 
received low-dose hydrocortisone (8–10 mg/h). Notably, 
mean adiponectin levels of patients receiving hydrocorti-
sone were almost identical with those of patients receiving 
no hydrocortisone (10.3 µg/mL vs 10.0 µg/mL). Also, both 
groups had similar SAPS II and SOFA scores.
Resistin, a protein with proinflammatory properties 
secreted by adipocytes and monocytes, has recently been 
reported to participate in the inflammatory response.24 
Secretion of resistin is stimulated by insulin and inflamma-
tory processes, glucocorticoids, and lipopolysaccharides, 
whereas tumor necrosis factor α and β-adrenergic stimulation 
act as inhibitors. Resistin levels are generally more elevated 
in obese patients and those with T2DM.25 Elevated resistin 
levels also seem to play a crucial role in insulin resistance.26 
Resistin levels were positively correlated with SAPS 
II score (r = 0.39, P = 0.03) and epinephrine demand 
(r = 0.43; P = 0.02) supporting participation of resistin in the 
inflammatory response process. On the other hand, gender 
specific adiponectin, a protein with anti-inflammatory or 
Table 2 Correlation of adipokines with insulin and epinephrine application in patients with sepsis (correlation coefficient r and 
P values)
Correlation of With All patients Female Male
insulin Adiponectin 0.57; <0.01 0.61; 0.05 0.53; 0.01
insulin Leptin 0.29; 0.08 -0.24; 0.28 0.53; 0.014
insulin resistin 0.13; 0.27 -0.02; 0.48 0.24; 0.18
insulin Hydrocortisone 0.52; P < 0.01 0.36; 0.19 0.59; <0.01
insulin BMi 0.19; 0.19 0.12; 0.39 0.22; 0.20
epinephrine Adiponectin -0.54; <0.01 -0.36; 0.19 -0.58; <0.01
epinephrine resistin 0.43; 0.02 0.79; 0.01 0.23; 0.19
BMi Adiponectin -0.17; 0.21 -0.37; 0.18 -0.16; 0.27
BMi Leptin 0.60; <0.01 0.61; 0.05 0.59; <0.01
BMi resistin 0.17; 0.21 0.68; 0.03 -0.02; 0.47
Note: Bold values indicate significant positive or negative correlations.
Abbreviation: BMi, body mass index.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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insulin-sensitizing properties27 showed a negative correlation 
with epinephrine demand – especially in male patients 
(r = -0.58; P , 0.01).
This study had several limitations: it had a small sample 
size, and male patients were significantly younger than female 
patients. However, patient age failed to show any significant 
correlation with the various analyzed values. Adipokines 
were analyzed only once, rather than at several time points 
through the septic course. Hydrocortisone substitution was 
performed only in patients with septic shock, with expected 
prolonged use of epinephrine infusion to maintain mean 
arterial pressure. Another crucial point was the self-reported/
estimated bodyweight and the heterogeneity of the septic 
group including patients with different causes of sepsis. This 
case mix reflects the typical clinical situation in intensive 
care units, however.
This study intended to explore the relationship between 
adipokine levels and insulin demand in critically ill patients. 
It represents an explorative study that hypothesized a possible 
trend, namely, that the relationship between adiponectin 
and insulin action in humans is more complex than often 
suggested.28
Conclusion
An unexpected positive correlation between adiponectin 
levels and insulin demand was found during sepsis. 
Adiponectin levels correlated negatively with epinephrine 
demand in male patients. On the other hand, epinephrine 
demand showed a positive correlation with resistin levels, 
which might have increased insulin resistance. Taken 
together, the sum effect of all the variables involved might 
have outweighed the expected negative correlation between 
insulin demand and adiponectin.
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